Philip Clingan

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

Joachim von Pawel, Robert M. Jotte, David R. Spigel et al. · Journal of Clinical Oncology · 2014 · 344 citations · Full text

Medicine, Oncology, Pharmacology +13

REVIEW OF PATIENTS WITH PERITONEAL MALIGNANCY TREATED WITH PERITONECTOMY AND HEATED INTRAPERITONEAL CHEMOTHERAPY

Reema Hadi, Vanessa Saunders, Olga Utkina et al. · ANZ Journal of Surgery · 2006 · 38 citations

Medicine, Oncology, Surgery +13

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

David R. Spigel, Afshin Dowlati, Yuanbin Chen et al. · Journal of Clinical Oncology · 2024 · 35 citations · Full text

Medicine, Oncology, Pharmacology +15

Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study

Marina Chiara Garassino, Shirish M. Gadgeel, Emilio Esteban et al. · Cancer Research · 2019 · 23 citations

Medicine, Oncology, Pharmacotherapy +16

Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC

Leena Gandhi, Delvys Rodgríguez-Abreu, Shirish M. Gadgeel et al. · Cancer Research · 2018 · 12 citations

Medicine, Oncology, Pharmacology +15